A randomized, controlled trial (RCT) shows that even at a higher dose and longer treatment duration, the antimalarial drug ivermectin didn't shorten the time to a sustained recovery from COVID-19.
People with asthma in Hong Kong experienced worse control of their asthma after they had recovered from mild to moderate COVID-19, according to findings yesterday in Respiratory Research.
Recent Comments